Disc Medicine (NASDAQ:IRON) Director Kevin Bitterman Sells 754 Shares

Disc Medicine, Inc. (NASDAQ:IRON) Director Kevin Bitterman sold 754 shares of the business’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $91.47, for a total transaction of $68,968.38. Following the sale, the director directly owned 14,013 shares in the company, valued at $1,281,769.11. This trade represents a 5.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Kevin Bitterman also recently made the following trade(s):

• On Friday, December 12th, Kevin Bitterman sold 45,507 shares of Disc Medicine stock. The shares were sold at an average price of $92.39, for a total value of $4,204,391.73.
• On Tuesday, December 16th, Kevin Bitterman sold 68,923 shares of Disc Medicine stock. The stock was sold at an average price of $91.24, for a total value of $6,288,534.52.
• On Monday, December 15th, Kevin Bitterman sold 62,693 shares of Disc Medicine stock. The shares were sold at an average price of $91.28, for a total value of $5,722,617.04.
• On Monday, December 15th, Kevin Bitterman sold 7,000 shares of Disc Medicine stock. The shares were sold at an average price of $91.87, for a total value of $643,090.00.
• On Friday, October 17th, Kevin Bitterman sold 70,000 shares of Disc Medicine stock. The stock was sold at an average price of $88.91, for a total value of $6,223,700.00.
• On Thursday, October 16th, Kevin Bitterman sold 1,425 shares of Disc Medicine stock. The shares were sold at an average price of $77.11, for a total value of $109,881.75.
• On Wednesday, October 15th, Kevin Bitterman sold 22,160 shares of Disc Medicine stock. The shares were sold at an average price of $77.23, for a total transaction of $1,711,416.80.
• On Wednesday, October 8th, Kevin Bitterman sold 71,961 shares of Disc Medicine stock. The stock was sold at an average price of $70.58, for a total transaction of $5,079,007.38.
• On Tuesday, October 7th, Kevin Bitterman sold 18,039 shares of Disc Medicine stock. The shares were sold at an average price of $68.38, for a total transaction of $1,233,506.82.

Disc Medicine Trading Up 3.4%

Disc Medicine stock opened at $90.44 on Friday. The stock has a 50-day simple moving average of $87.72 and a 200 day simple moving average of $68.51. The stock has a market capitalization of $3.41 billion, a P/E ratio of -16.90 and a beta of 0.87. The company has a debt-to-equity ratio of 0.05, a quick ratio of 23.45 and a current ratio of 23.45. Disc Medicine, Inc. has a 52 week low of $30.82 and a 52 week high of $99.50.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings data on Thursday, November 6th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.48) by ($0.29). Analysts expect that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Analysts Set New Price Targets

IRON has been the subject of a number of research analyst reports. Morgan Stanley lifted their price objective on shares of Disc Medicine from $90.00 to $115.00 and gave the stock an “overweight” rating in a research report on Thursday, October 30th. National Bankshares set a $153.00 target price on shares of Disc Medicine in a report on Friday, October 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a report on Wednesday, October 8th. Raymond James Financial restated a “strong-buy” rating and set a $117.00 price objective on shares of Disc Medicine in a research report on Monday, December 8th. Finally, Wells Fargo & Company upped their target price on Disc Medicine from $91.00 to $109.00 and gave the company an “overweight” rating in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $119.00.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in Disc Medicine by 22.2% during the first quarter. Vanguard Group Inc. now owns 1,305,046 shares of the company’s stock worth $64,782,000 after purchasing an additional 236,800 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Disc Medicine by 18.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 194,725 shares of the company’s stock valued at $9,666,000 after buying an additional 29,653 shares in the last quarter. Swiss National Bank lifted its holdings in shares of Disc Medicine by 11.5% during the 1st quarter. Swiss National Bank now owns 35,900 shares of the company’s stock worth $1,782,000 after acquiring an additional 3,700 shares during the period. Invesco Ltd. lifted its holdings in shares of Disc Medicine by 27.1% during the 1st quarter. Invesco Ltd. now owns 13,834 shares of the company’s stock worth $687,000 after acquiring an additional 2,953 shares during the period. Finally, Nuveen LLC acquired a new stake in shares of Disc Medicine during the 1st quarter worth approximately $5,595,000. Institutional investors own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.